INS and type 2 diabetes mellitus: In patients with type-II diabetes, severe hypoglycaemic events occurred in 5.1% of patients treated with TI, versus 1.7% hypoglycaemic events treated with placebo (Technosphere powder without insulin), and non-severe hypoglycaemia occurred in 67% versus 30%, respectively [54].